1-2 of 2
Keywords: Long-term efficacy
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice

Available to Purchase
Subject Area:
Gastroenterology
Ken Sugimoto, Kentaro Ikeya, Masaichi Kato, Ai Matsuura, Fumitoshi Watanabe, Ryosuke Takano, Satoshi Tamura, Shinya Tani, Satoshi Osawa, Hiroyuki Hanai
Journal: Digestive Diseases
Dig Dis (2018) 37 (1): 11–20.
https://doi.org/10.1159/000493121
Published Online: 11 September 2018
..., there are a limited number of reports on the long-term efficacy of adalimumab. This study was to understand baseline demographic features, which potentially could be risk factors for relapse or colectomy following induction of remission by adalimumab in UC patients. Additionally, factors affecting long-term outcomes...
View articletitled, Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice
Open the PDF for Assessment of Long-Term Efficacy and Safety of Adalimumab in Patients with Ulcerative Colitis: Results from a 6-Year Real-World Clinical Practice in another window
Journal Articles

Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey

Available to Purchase
Subject Area:
Gastroenterology
Stephan R. Vavricka, Milos Spasojevic, Gerhard Rogler, Alain M. Schoepfer, Frank Seibold, Jan Borovicka, Pascal Frei, Jonas Zeitz, Thomas Greuter, Christine Manser, Michael Scharl, Benjamin Misselwitz, Alex Straumann, Pierre Michetti, Luc Biedermann, for the Swiss IBDnet
Journal: Digestive Diseases
Dig Dis (2017) 35 (5): 423–432.
https://doi.org/10.1159/000475494
Published Online: 09 June 2017
... of certolizumab pegol (CZP) in Crohn's disease (CD) from pivotal registry trials are limited. We therefore aimed to evaluate the long-term efficacy of CZP in clinical practice in Switzerland. Methods: In the First Approved Certolizumab Therapeutic Experience in Switzerland-III phase IV multicenter cohort...
View articletitled, Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey
Open the PDF for Long-Term Efficacy and Safety of Certolizumab Pegol in an Unselected Crohn's Disease Population: The FACTS III Survey in another window